Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by Fmr LLC

Fmr LLC trimmed its holdings in shares of Arbutus Biopharma Co. (NASDAQ:ABUS) by 17.4% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 83,280 shares of the biopharmaceutical company’s stock after selling 17,538 shares during the quarter. Fmr LLC’s holdings in Arbutus Biopharma were worth $321,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in ABUS. nVerses Capital LLC acquired a new stake in Arbutus Biopharma during the second quarter worth about $34,000. Helen Stephens Group LLC purchased a new stake in Arbutus Biopharma in the 3rd quarter worth approximately $50,000. XTX Topco Ltd purchased a new stake in Arbutus Biopharma in the 2nd quarter worth approximately $53,000. Premier Path Wealth Partners LLC grew its stake in shares of Arbutus Biopharma by 18.0% during the 2nd quarter. Premier Path Wealth Partners LLC now owns 36,000 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 5,500 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its holdings in shares of Arbutus Biopharma by 63.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 36,309 shares of the biopharmaceutical company’s stock valued at $140,000 after purchasing an additional 14,138 shares in the last quarter. 43.79% of the stock is owned by hedge funds and other institutional investors.

Arbutus Biopharma Stock Performance

NASDAQ:ABUS opened at $3.21 on Friday. The company has a fifty day moving average of $3.71 and a two-hundred day moving average of $3.69. Arbutus Biopharma Co. has a fifty-two week low of $2.21 and a fifty-two week high of $4.72. The stock has a market capitalization of $608.27 million, a PE ratio of -7.46 and a beta of 1.84.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on ABUS shares. Chardan Capital reissued a “buy” rating and set a $5.00 price target (up from $4.50) on shares of Arbutus Biopharma in a report on Wednesday, November 20th. Jefferies Financial Group upped their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the stock a “buy” rating in a research report on Thursday, September 5th. JMP Securities raised their target price on Arbutus Biopharma to $5.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Arbutus Biopharma in a report on Monday, November 18th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.

Arbutus Biopharma Profile

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression.